2018
DOI: 10.18632/oncotarget.26059
|View full text |Cite
|
Sign up to set email alerts
|

Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family

Abstract: Nature is always the best inspiration for basic research. A family with severe thrombosis and antithrombin deficiency, the strongest anticoagulant, carried a new mutation affecting the translation-start codon of SERPINC1, the gene encoding antithrombin. Expression of this variant in a eukaryotic cell system produced three different antithrombins. Two downstream methionines were used as alternative initiation codons, generating highly expressed small aglycosylated antithrombins with cytoplasmic localization. Wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 39 publications
0
2
0
Order By: Relevance
“…Type I: Classical deficiency, characterized by impaired AT synthesis and a parallel decrease in plasma AT antigen and activity in patients. Its clinical manifestations are severe and usually associated with severe mutations in SER-PINC1, which lead to a significant decrease in the level of AT in plasma owing to mutations that destabilize mRNA, misfolded proteins, and intracellular retention, or lead to abnormal degradation [21][22][23]. Type II mainly affects the domain function bound to thrombin or heparin, with normal plasma AT antigen content, but its activity is weakened [24], its clinical manifestations are mild, and its incidence is relatively high [25].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Type I: Classical deficiency, characterized by impaired AT synthesis and a parallel decrease in plasma AT antigen and activity in patients. Its clinical manifestations are severe and usually associated with severe mutations in SER-PINC1, which lead to a significant decrease in the level of AT in plasma owing to mutations that destabilize mRNA, misfolded proteins, and intracellular retention, or lead to abnormal degradation [21][22][23]. Type II mainly affects the domain function bound to thrombin or heparin, with normal plasma AT antigen content, but its activity is weakened [24], its clinical manifestations are mild, and its incidence is relatively high [25].…”
Section: Discussionmentioning
confidence: 99%
“…SERPINC1 encodes 32 amino acid signal peptides and 432 amino acid maturation proteins [38,39]. The primary function of this signal peptide is to direct nascent polypeptide chains into the endoplasmic reticulum, followed by post-translational processing, including disulfide bond formation, N-glycosylation, signal peptide cleavage, and correct folding of the protein into a metastable conformation, which is required for the inhibitory activity of this serine protease inhibitor [22]. A portion of exons 2 and 3 encodes the heparin-binding site region [40].…”
Section: Discussionmentioning
confidence: 99%